Estudos Randomizados

Estudo randomizado transversal com 12 pacientes mostrou que um “pâncreas artificial” bi-hormonal com controle glicêmico em circuito fechado aumentou o tempo do paciente em euglicemia após pancreatectomia total.

13 Set, 2022 | 11:58h

Bihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy: A Randomized Clinical Trial – JAMA Surgery (gratuito por tempo limitado)

Comentário: Novel Bihormonal Artificial Pancreas Beneficial After Pancreatectomy – HealthDay

Estudo randomizado | Efeitos da administração do nicorandil no tamanho do infarto de pacientes com infarto do miocárdio com elevação do segmento ST submetidos a intervenção coronariana percutânea primária.

13 Set, 2022 | 11:52h

Effects of Nicorandil Administration on Infarct Size in Patients With ST‐Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The CHANGE Trial – Journal of the American Heart Association

Estudo randomizado | Atezolizumabe adjuvante não melhorou os desfechos de pacientes com carcinoma de célula renal sob risco aumentado de recorrência após a ressecção.

13 Set, 2022 | 11:44h

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Comentários:

Adjuvant atezolizumab falls short in renal cell carcinoma – Urology Times

IMmotion010 does not support adjuvant atezolizumab in intermediate-, high-risk RCC – medwire News

Comentário do autor no Twitter (fio – clique para saber mais)

Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY pic.twitter.com/klAYWAQVwV

— Sumanta Pal (@montypal) September 10, 2022

Estudo randomizado | Busulfam com ciclofosfamida é não inferior à irradiação corpórea total com ciclofosfamida para adultos com leucemia linfoblástica B aguda.

13 Set, 2022 | 11:42h

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial – Journal of Clinical Oncology

Estudo randomizado | Sobrevida global com olaparibe de manutenção em um seguimento de 7 anos de pacientes com câncer de ovário avançado recém-diagnosticado e mutação no BRCA.

13 Set, 2022 | 11:40h

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial – Journal of Clinical Oncology

Comentário: Olaparib Maintenance Provides Sustained OS Benefit in Newly Diagnosed, BRCA-Mutated, Advanced Ovarian Cancer – OncLive

Estudo randomizado | Sulopeném (tem formulações oral e IV) não atingiu os critérios para não inferioridade em comparação ao ertapeném no tratamento de infecções complicadas de trato urinário, incluindo pielonefrite.

12 Set, 2022 | 11:27h

Sulopenem For The Treatment of Complicated Urinary Tract Infection Including Pyelonephritis: A Phase 3 Randomized Trial – Clinical Infectious Diseases

Estudo randomizado | Lenalidomida-dexametasona vs. observação no mieloma latente de alto risco após 12 anos de seguimento médio.

12 Set, 2022 | 11:24h

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study – European Journal of Cancer (link para o resumo – $ para o texto completo)

Seguimento de 48 semanas de um estudo randomizado | Pegcetacoplan vs. eculizumabe em pacientes com hemoglobinúria paroxística noturna.

12 Set, 2022 | 11:16h

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link para o resumo – $ para o texto completo)

Estudo original: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine

Comentário no Twitter (fio – clique para saber mais)

NEW research—Duration of improved haem outcomes and favourable safety over 48 weeks suggests that pegcetacoplan has the potential to alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria: long-term results of PEGASUS #PNH https://t.co/dpT5cDih8X

— The Lancet Haematology (@TheLancetHaem) September 1, 2022

Estudo randomizado | Ripretinibe vs. sunitinibe em pacientes com tumor estromal gastrintestinal avançado após tratamento com imatinibe.

12 Set, 2022 | 11:08h

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial – Journal of Clinical Oncology

Editorial: Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine – Journal of Clinical Oncology

Comentário no Twitter

👀 INTRIGUE Trial: Ipretinib not superior to sunitinib but demonstrates longest median progression free survival ever in advanced #GastrointestinalStromalTumor ➡️ https://t.co/aUNdvXaQcH #GIST #scmsm @seppobauer pic.twitter.com/pPfph6A8Lr

— Journal of Clinical Oncology (@JCO_ASCO) August 24, 2022

Estudo randomizado | Terapia em circuito fechado híbrido avançado vs. tratamento convencional em adultos com diabetes tipo 1.

8 Set, 2022 | 14:11h

Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study – The Lancet Endocrinology (link para o resumo – $ para o texto completo)

Comentário: ‘Artificial Pancreas’ Best in Poorly Controlled Type 1 Diabetes – Medscape (necessário cadastro gratuito)